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Raynaud’s phenomenon (RP) is characterized by exaggerated cold-induced
vasoconstriction. This augmented vasoconstriction occurs by virtue of a reflex
response to cooling via the sympathetic nervous system as well as by local
activation of α2C adrenoceptors (α2C-AR). In a cold-initiated, mitochondrion-mediated
mechanism involving reactive oxygen species and the Rho/ROCK pathway, cytoskeletal
rearrangement in vascular smooth muscle cells orchestrates the translocation of α2C-
AR to the cell membrane, where this receptor readily interacts with its ligand. Different
parameters are involved in this spatial and functional rescue of α2C-AR. Of notable
relevance is the female hormone, 17β-estradiol, or estrogen. This is consistent with
the high prevalence of RP in premenopausal women compared to age-matched males.
In addition to dissecting the role of these various players, the contribution of pollution
as well as genetic background to the onset and prevalence of RP are also discussed.
Different therapeutic approaches employed as treatment modalities for this disease are
also highlighted and analyzed. The lack of an appropriate animal model for RP mandates
that more efforts be undertaken in order to better understand and eventually treat this
disease. Although several lines of treatment are utilized, it is important to note that
precaution is often effective in reducing severity or frequency of RP attacks.
Keywords: Raynaud’s Phenomenon, peripheral vascular disease, alpha 2-adrenergic receptors, estrogen,
thermoregulation, Rho kinase
INTRODUCTION
Cold-induced vasoconstriction of cutaneous arterioles is a normal physiological process that
redirects blood from the superficial circulation to internal organs in order to protect the body
from excessive heat loss (Charkoudian, 2010). This constriction is mediated by reflex sympathetic
release of norepinephrine (Charkoudian, 2010) as well as increased sensitization of the vasculature
(Vanhoutte, 1980; Wigley and Flavahan, 2016). When this cold-induced constriction is exaggerated,
it leads to a pathological condition known as Raynaud’s phenomenon (RP) (Herrick, 2012). This
disease can be clinically classified as primary or secondary (Block and Sequeira, 2001). Primary RP
is idiopathic, and it is the most common form of the disease (Roustit et al., 2014). On the other
hand, Secondary RP could be due to myriad of underlying health conditions such as autoimmune
diseases or cancer, as well as lifestyle conditions such as smoking or certain medications
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(Prete et al., 2014). Indeed, 95% of patients suffering from
Scleroderma are diagnosed with RP (Black, 1995).
Raynaud’s phenomenon affects up to 10% of the general
population (Garner et al., 2015). Affected individuals suffer from
cold-provoked vasospastic attacks (Heidrich, 2010) which are
associated with the classic triple-color change (pallor, cyanosis,
and erythema) (Maverakis et al., 2014), in addition to puffiness
and ulcerations mainly at the level of fingers (Gerbracht et al.,
1985). Other distal body organs such as the nose, toes, and
nipples are reported to be affected (Block and Sequeira, 2001;
Anderson et al., 2004). While there are different manifestations
that can be used to diagnose RP, changes in some parameters
may also be helpful. For example, serological tests of RP patients
show increased levels of endothelin-1 (Zamora et al., 1990),
tumor necrosis factor-α (TNF-α) (Rychlik-Golema et al., 2006),
fibrinogen (Spengler et al., 2004), platelet factor (PF-4), and
von Willebrand’s factor (vWF) (Rychlik-Golema et al., 2006).
Magnesium ions and S-nitrosothiols levels appear to decrease in
RP patients compared to unaffected individuals (Leppert et al.,
1990; Kundu et al., 2014). Furthermore, anti-centromere and
anti-centriole antibodies are detected in patients’ sera (Gentric
et al., 1990; Yamada et al., 2014).
Many hypotheses have been proposed to dissect and explain
the underlying mechanisms implicated in the pathogenesis
of RP. Recent evidence appears to lend strong support for
the mosaic theory of this disease (Greenstein et al., 1996).
This theory consolidates the multi-etiology of the disease,
involving local, neuronal, and hormonal mediators (Wigley,
2002). Impaired function of any of these mediators may
contribute to an exaggerated constriction of cutaneous arteries
in response to noradrenaline (Easter and Marshall, 2005).
Noradrenaline elicits its effects through binding to adrenergic
receptors located on the surface of vascular smooth muscle
cells (VSMCs) (Guimaraes and Moura, 2001). Typically, VSMCs
have three types of adrenergic receptors (ARs): α1, α2, and β2.
Depending on the vascular bed, β1 and β3 adrenoceptors may
also be present but usually with a lower expression than β2
adrenoceptors (Ahles and Engelhardt, 2014). β2 adrenoceptors
are involved solely in vasodilation (McCance and Huether, 2013),
whereas α1 and α2-ARs are responsible for vasoconstriction
(Figure 1A). While α1-ARs have a wide expression pattern
across the vascular tree, α2-ARs are predominantly present in
smaller blood vessels or arterioles (Polonia et al., 1985). At one
point, these receptors were surprisingly found to be present
in the protein extract of minced aortas (Chotani et al., 2004).
However, histochemical analysis showed that these receptors
were expressed in the vasa vasorum of the aorta (Chotani et al.,
2004).
Early evidence clearly pointed to the prominent role of
α2-ARs in local cooling-induced constriction of cutaneous
arteries. It is important to note that local cooling causes
vasodilation (Johnson and Kellogg, 2010) as well as inhibits
α1-AR-mediated vasoconstriction (Freedman et al., 1992).
Paradoxically, this very cooling also causes vasoconstriction by
virtue of its potential to selectively amplify α2-AR-mediated
constrictive effects (Jeyaraj et al., 2001; Eid et al., 2008). Because
they play the key role in the sympathetic constriction of
cutaneous vessels, selective potentiation of α2-ARs allows their
cold-induced constrictive effects to overcome the vasodilatory
effects. Accordingly, non-selective α2-AR antagonists were, at one
point, used to treat peripheral cold-induced vasoconstriction but
were not therapeutically effective (Freedman et al., 1993).
Molecular, genetic, and pharmacologic studies show that
α2-ARs actually comprise three subtypes: α2A, α2B, and
α2C (MacDonald et al., 1997). These subtypes have their
corresponding genes on three different chromosomes, and
they are all coupled to inhibitory hetero-trimeric G protein
(MacDonald et al., 1997). The search for the particular subtype
responsible for α2-AR-mediated cold-induced vasoconstriction
remained unclear for some time. α2A-ARs did not seem to play
any role in cold-induced constriction (Chotani et al., 2000). Some
reports pointed to the potential use of α2B-AR antagonists as a
treatment option for vasospasms in RP (MacDonald et al., 1997).
Much to our surprise, we could not find strong experimental or
clinical data that support a role for α2B-AR antagonists in the
treatment of Raynaud’s Disease.
Of the α2-AR subtypes, α2C-AR was thought to be a vestigial
receptor for two main reasons. The first is that α2C-ARs are
sequestered in an intracellular compartment (von Zastrow and
Kobilka, 1994), and thus their function was not easily detected
by immunohistochemistry assays (MacDonald et al., 1997). The
second is that neither the α2C-AR knockout nor the transgenic
mice showed major changes; both remained viable, fertile, and
almost normal (Sallinen et al., 1997). On the other hand, other
evidence emerged to argue against the apparent vestigiality
of α2C-AR. First, α2C-ARs exhibit highly conserved domains
present in other adrenoceptors (Nyronen et al., 2001). Second,
the apparently normal phenotype may be due to compensation
by other α2-ARs, and third, α2C-ARs are differentially expressed
in cells of different tissues (MacDonald et al., 1997).
One interesting and rather unique feature of its biology is that
upon certain physiologic and pathophysiologic stimuli, α2C-AR
can translocate from the endoplasmic reticulum (ER) and Golgi
apparatus to the cell membrane. This spatial rescue renders the
receptor available for its ligand, whose binding then activates the
receptor (Chotani et al., 2000, 2004; Jeyaraj et al., 2001). Upon
moderate physiological cooling (i.e., 28◦C), α2C-AR is mobilized
from the ER/Golgi to the cell surface (Bailey et al., 2004). The
now membrane-localized receptors can readily interact with their
agonists, become activated and evoke cutaneous vasoconstriction
in response to norepinephrine (Jeyaraj et al., 2001). Indeed, it
is now evident that the entirety of cold-induced constriction of
cutaneous arteries is due to an increased activity of α2C-ARs
(Bailey et al., 2004; Eid et al., 2008). As such, α2C-ARs appear
to play an important role in the augmented vasoconstriction
observed in RP (Bailey et al., 2004).
The mechanism by which α2C-AR translocation takes place
involves different players such as reactive oxygen species (ROS),
Rho/Rho kinase, and the actin cytoskeleton (Figure 1B). Bailey
et al. reported that the Rho/Rho kinase pathway becomes
activated as early as few minutes after cells get exposed to cold
temperatures (Bailey et al., 2004). The now active Rho evokes
the mobilization of α2C-AR to the membrane, and consequently
triggers cold-induced vasoconstriction (Bailey et al., 2004).
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FIGURE 1 | (A) Predominant adrenergic receptors in arteriolar vascular smooth muscle cells (VSMC). β2AR mediates mediates vasodilation of small microvessels.
Vasoconstriction of these vessels occurs via α1-AR, α2A-AR, and α2C-AR. Whereas α1-, α2A-, and β2-ARs in these cells are localized at the cell surface, α2C-AR (in
dotted orange circle) is uniquely trapped intracellularly (mostly trans-Golgi). However, it can be mobilized to the membrane by various stimuli such as cold
temperatures. α2C-AR mediates cold-induced vasoconstriction, which when exacerbated may lead to Raynaud’s phenomenon (RP). (B) Mechanism of cold-induced
mobilization of α2C-AR. In cutaneous arteriolar SMCs, a decrease in temperature is sensed by the mitochondria, which then releases reactive oxygen species (ROS).
ROS, in turn, activates the Rho/ROCK pathway. Subsequent cytoskeletal rearrangements involving F-actin and filamin-2 promote mobilization of α2C-AR from the
endoplasmic reticulum/Golgi to the cell surface.
In this sense, it seems that Rho, rather than α2C-AR, is
the “thermosensor” (Bailey et al., 2004). However, additional
and rather elegant investigations from the Flavahan group
further showed that the mitochondrion is the “thermo-sensitive”
organelle in VSMCs (Bailey et al., 2005). Indeed, upon cold stress,
it is the mitochondria that initiate the process by releasing ROS,
which in turn triggers a redox signal that activates the Rho/Rho
kinase pathway leading to spatial redistribution and functional
activation of α2C-ARs (Bailey et al., 2005). This cooling-induced
Rho activation may then act through calcium sensitization or via
modulation of cytoskeletal architecture (Hall, 1998; Jeyaraj et al.,
2001; Chitaley and Webb, 2002).
RP AND THE ACTIN CYTOSKELETON
The cytoskeleton plays a major role in fundamental cellular
processes like cell division, migration, cell-cell communication,
and protein trafficking (Fletcher and Mullins, 2010). The
translocation of α2C-ARs, a main player in RP, from the
ER/Golgi to the cell membrane of VSMCs is critical for their
activation. This translocation involves many cytoskeletal
components such as F-actin and actin/myosin filaments.
It is through modulation of the actomyosin filaments
that VSMC contraction and ultimately vasoconstriction
occur.
Cold-induced, Rho-mediated architectural change occurs
by virtue of a rearrangement of the actin superstructure
evident by an increase in F-actin, a downstream effector
of Rho kinase signaling (Jeyaraj et al., 2012). Interestingly,
immunocytochemical analysis shows that intracellular α2C-AR
and F-actin are sometimes found to be co-localized in non-
vascular cells (Hurt et al., 2000). In a rather elegant and
orchestrated series of events, α2C-ARs then get in close proximity
and associate with actin filaments, readying themselves for the
trafficking process (Jeyaraj et al., 2012). This intimate association
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FIGURE 2 | Evidence of positive association between estrogen and RP. Accumulating evidence points to an overwhelming association between estrogen and
RP. For instance, estrogen increases α2C-AR but not α2A-AR in human arteriolar smooth muscle cells. Moreover, females have higher expression of α2C-AR than
males. Epidemiologically, RP is reported to have remarkably high incidence in premenopausal females or post-menopausal females on estrogen replacement therapy
(ERT).
appears to be mediated by a direct interaction between α2C-
ARs and filamin-2, a cross-linker of actin filaments (Motawea
et al., 2013). Indeed, further in silico protein-protein docking
examinations confirmed that the interaction between α2C-AR
and F-actin occurs via the direct binding of α2C-AR to filamin,
the actin binding protein (Pawlowski et al., 2014). Interestingly,
this interaction has evolved only in warm blooded animals
(Pawlowski et al., 2014). Therefore, elucidation of similar protein-
protein interactions can help establish more efficient therapies
for exaggerated vasoconstriction. One scenario would include
approaches that seek to disrupt the interaction between α2C-AR
and the cytoskeletal component, F-actin.
RP AND ESTROGEN
Evidence from epidemiological studies reveals a rather interesting
finding regarding the prevalence of RP. There is a significantly
higher incidence of this disease in females versus age-matched
males (Maricq et al., 1993; Garner et al., 2015). Indeed, 70%
of all American patients suffering from RP are females (Maricq
et al., 1993). Among patients affected with RP, the ratio of
premenopausal females compared to age-matched males is
close to 9:1 (Belch and Ho, 2001). This clearly illustrates a
gender-based element in the prevalence of the disease, and
thus hints to a potential role of sex hormones in its onset
or pathology (Maricq et al., 1993). Although it is reported
that cardiovascular diseases in general are more prevalent in
men and post-menopausal women (Reslan and Khalil, 2012),
being a female is among the risk factors of RP (Garner
et al., 2015). This conclusion is partly based on a meta-
analysis study asserting the much higher prevalence in females
compared to males (Garner et al., 2015). In particular, the
incidence is higher in premenopausal versus post-menopausal
women, with an interesting association between the menstrual
cycle and cold-modulated digital blood flow (Greenstein et al.,
1996). Further analysis revealed that post-menopausal females
receiving unopposed estrogen replacement therapy (ERT) are
more likely to suffer from the disease than post-menopausal
women that are not receiving ERT (Mayes, 1999). Together,
these findings demonstrate that estrogen may explain the higher
incidence in premenopausal women (Figure 2). Interestingly,
in post-menopausal women receiving opposed estrogen therapy
(estrogen and progesterone together), the incidence of RP was
not significantly higher than that in premenopausal women
(Fraenkel et al., 1998). This may suggest that progesterone
negates estrogen’s effect in this context, but this remains to be
established.
It is worth mentioning that in premenopausal females,
noradrenaline-mediated vasoconstriction is higher at the mid-
menstrual cycle, characterized by relatively high estrogen level,
than during the early stage of the cycle (Chan et al., 2001).
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FIGURE 3 | Genetic basis of RP. The genetic basis of RP is supported by familial studies and twin analysis in addition to a reported case of a 1-month male baby
diagnosed with the disease. Furthermore, a combination of positive genotypes for both genes encoding glutathione S-transferase M1 and T1 subtypes may have a
role in susceptibility to RP. Linkage analysis pinpointed five areas corresponding to three candidate genes (β-subunit of muscle acetylcholine receptor, 1E and 1B
serotonin receptors) which could be associated to RP.
Moreover, human and rat females of reproductive age exhibit
higher vascular responsiveness than males (Li et al., 2014).
Interestingly, male vascular responsiveness is potentiated
when 17β-estradiol is externally supplemented (Li et al.,
2014). This implies that estrogen has a direct effect on
vasoreactivity, though the mechanisms for such potentiation
remain unclear.
The fundamental role of estrogen in regulating body
temperature has been defined (Charkoudian and Stachenfeld,
2016). Although estrogen has a vasodilatory effect, it may in
many instances decrease body temperature (Charkoudian and
Stachenfeld, 2016). Since RP can be considered a vascular
thermoregulatory control disorder (Flavahan, 2015), the
implication of estrogen in the disease becomes obvious
especially in light of the exaggerated response to cold in
premenopausal women as well as the higher prevalence of
RP in younger females. This is further supported by the
findings of English et al. that there is a gender difference
in vasomotor activities in response to estrogen, and that
this difference may be a critical contributor to the etiology
of vasospastic diseases (English et al., 2001), such as
RP.
Evidence indicates that estrogen increases α2C-AR
expression in VSMCs and that α2C-AR-mediates cold-induced
vasoconstriction in rat tail arteries (Eid et al., 2007). A notable
finding is that among the α2-ARs, only the α2C-AR subtype is
differentially expressed in rat tail arteries, with a remarkably
greater expression in females (McNeill et al., 1999). We had also
reported that in human VSMCs, estrogen does not modulate
the expression of α2A-AR (Eid et al., 2007). The Flavahan
group had also established that α2C-AR mediates the entirety
of cold-induced vasoconstriction. We then hypothesized and
later confirmed that estrogen indeed increases the expression,
surface-localization, and function of α2C-AR (Eid et al., 2007).
This estrogen-induced activity of α2C-AR was followed by a
potentiated cold-induced vasoconstrictive response in mouse
tail arteries (Eid et al., 2007). Collectively, these pieces of
evidence highlight a positive association between estrogen
and RP.
RP AND GENETIC BACKGROUND
As mentioned earlier, RP is either idiopathic, or secondary
to another disease like scleroderma. There have been some
speculations that genetic predisposition may be a contributor
to the onset of this disease (Tan and Arnett, 2000) (Figure 3).
However, sequencing results showed no mutations in candidate
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genes that are suspected to play a role in the etiology of the disease
(Susol et al., 2000). These candidate genes are the beta subunit
of the muscle acetylcholine receptor and the serotonin 1B and
1E receptors (Susol et al., 2000). Nonetheless, others continued
to suggest that there is a genetic factor contributing to the
prevalence of this disease (Pistorius et al., 2006). This assertion
is supported by familial studies and twin analysis (Pistorius et al.,
2006). Recently, there was a reported case of a 1 month male baby
diagnosed with RP (Sharathkumar and Castillo-Caro, 2011). In
light of this case, it was speculated that there could be a genetic
basis of the disease. However, much evidence remains lacking
before a strong causative link between genetics and RP can be
affirmed.
Interestingly, studies of RP patients that were exposed to vinyl
chloride monomer (VCM) suggest that the interaction between a
certain genetic background and environmental conditions may
play a role in increasing the onset of RP in VCM-exposed
individuals (Fontana et al., 2006). In 2006, Fontana et al.
(2006) investigated whether there is an association between
polymorphisms in glutathione S-transferase M1 and T1 genes
and RP patients exposed to VCM (Fontana et al., 2006). The
results showed that the combination of positive genotypes for
both genes may increase susceptibility to RP (Fontana et al.,
2006). In another study, using 298 microsatellite markers, a two-
stage whole genome screen of six extended families having at
least three RP patients in each family was undertaken (Susol
et al., 2000). Linkage analysis identified five chromosomal areas
of possible linkage. These were mapped to three candidate genes
(β-subunit of muscle acetylcholine receptor, 1E and 1B serotonin
receptors) which could be associated with RP (Susol et al., 2000).
This provides evidence of a genetic basis for RP susceptibility.
The fact that five possible linkages were highlighted indicates
that RP may be an oligogenic rather than monogenic condition.
However, more research is needed to ascertain this suggestion,
since some of the findings reported may be false positives (Susol
et al., 2000). It would, therefore, be interesting to screen in a large
pool of RP patients, for mutations or SNPs in these candidate
genes.
TOXICOLOGICAL BASIS OF RP
Many of the heightened vasoreactivity responses observed in
RP are due to either sympathetic or local causes. Stressors
such as cold temperatures or emotional anxieties fall under
the sympathetic category, since they cause vasoconstriction via
noradrenaline. On the other hand, mechanical and chemical
stresses fall under the “local” category since they directly affect a
body organ that will show symptoms of the disease. A prominent
body area that could be affected by these “local” insults would
be the digits. Prolonged exposure to vibration at the level
of the hand and arm is an example of mechanical stress.
Also known as vibration-induced white finger, this hand-arm
vibration syndrome is indeed one form of secondary RP that
is due to occupational hazards (White et al., 2004). Continuous
insults of the hand and arm by vibrating machines can prime
these organs for increased vasospastic attacks upon a thermal or
emotional stress. With the progression of this condition, such
vibration can cause increased digital vasospasm even at room
temperature (White et al., 2004). Therefore, it is not surprising
that vascular symptoms are highly prevalent among workers
whose job requires handling vibrating tools (White et al., 2004).
One of the prominent examples of chemical stressors in
RP is VCM. This monomer is a colorless gas used in the
manufacturing of plastic, particularly poly vinyl chloride (PVC).
Interestingly, almost one third of workers exposed to PVC suffer
from RP (Maricq et al., 1978). Angiography of these patients’
hands showed vascular tone changes and vascular lesions such as
narrowing of the digital arteries (Falappa et al., 1982). This is not
surprising since angiographic and capillaroscopic examinations
have shown that exposure to VCM is toxic for the endothelium
(Maricq et al., 1976; Falappa et al., 1982). Furthermore, exposure
to VCM was shown to significantly contribute to acroosteolysis of
distal phalanges of hands, which was recurrently associated with
symptoms of RP (Wilson et al., 1967). Indeed, and as mentioned
earlier, a higher prevalence of RP among French workers exposed
to PVC was reported (Fontana et al., 2006). Taken together, these
observations support the notion that a persistent toxic effect of
polyvinyl chloride can contribute to the onset and pathogenesis
of RP.
There are other chemical compounds or even medicinal drugs
that are linked to the onset of RP. Some examples include
arsenic, nicotine, and the drug gemcitabine. Indeed, a positive
correlation seems to exist between Arsenic and RP. A study in
Chile shows that increased prevalence of signs and symptoms
of peripheral vascular disease, including RP, are associated
with Arsenic-contaminated drinking water (Nordberg et al.,
2014). Contextually, Arsenic-exposed smelter workers exhibit
heightened vasospastic reactivity in the fingers, reminiscent of
RP (Lagerkvist et al., 1986; Hall, 2002; William and Markowitz,
2007). Together, these findings provide some evidence of arsenic
being a player in the etiology of RP.
Smoking has been long found to positively associate with RP
(Garner et al., 2015). Moreover, nicotine, one main constituent
in tobacco, is known to significantly decrease blood flow and
increase vascular resistance (Cardelli and Kleinsmith, 1989). It is
thus not surprising that nicotine can exacerbate symptoms of RP
(Cherniack et al., 2000; Jackson, 2006), so much so that avoiding
nicotine has been suggested as one element in the treatment of
RP of the nipple (Anderson et al., 2004).
Some drugs such as gemcitabine, a nucleoside analog used
in chemotherapy (Carmichael, 1998), could evoke symptoms
reminiscent of RP (Yamada et al., 2014). Indeed, when orally
administered, it appears to cause pain, swelling, and whitening
of the digits, all of which are typical of RP (Carmichael,
1998). Indeed, a case of RP and digital necrosis after receiving
gemcitabine for bladder cancer has been reported (D’Alessandro
et al., 2003). Furthermore, a scleroderma patient developed
digital ischemia after receiving a combined treatment with
gemcitabine and carboplatin (Clowse and Wigley, 2003).
Interestingly, the association of gemcitabine chemotherapy
with digital ischemic events appear to be more common
than previously suspected, especially in patients with tobacco-
associated cancers (Kuhar et al., 2010). While the mechanisms
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for this gemcitabine-induced vascular insult remain unclear,
it is proposed that endothelial damage as well as thrombotic
microangiopathy (Venat-Bouvet et al., 2003; Holstein et al., 2010)
may be contributing factors. It is important to note that this
gemcitabine-associated vascular toxicity is rather pronounced in
scleroderma patients. Similarly, exacerbations of RP symptoms
were found to be associated with fluoropyrimidine, namely
capecitabine, therapy (Coward et al., 2005). As such, caution
should be taken when administering chemotherapeutic agents,
especially gemcitabine, to scleroderma or RP patients.
Chemotherapeutic agents, other than gemcitabine, have
also been associated with RP. For instance, doxorubicin, and
cyclophosphamide-induced scleroderma cases mostly present
with diffuse sclerosis and RP (Saif et al., 2016). Moreover,
vincristine-induced dose-dependent RP has been reported
(Gottschling et al., 2004). Interestingly, a higher prevalence
of RP is noted when cisplatin is combined with vinblastine
(Vogelzang et al., 1981). Whether the neurotoxic effects of these
drugs underpins the increase RP prevalence remains poorly
determined. It has been suggested that hyperreactivity in the
sympathetic outflow may be an underlying cause (Chant, 1987;
Olsen et al., 1987). However, this cannot exclude the possibility
that a direct effect on the vasculature of terminal arterioles
is also possible, especially that the entirety of cold-induced
vasoconstriction is mediated by vascular α2C-AR, independently
of any contribution from the endothelial or the sympathetic
nervous system (Kristensen, 1979; Eid et al., 2007, 2008; Wigley
and Flavahan, 2016).
Epidemiologic data derived from a long-term study involving
combined treatment with cisplatin, vinblastine, and bleomycin
chemotherapy showed that 35–45% of these treated patients
developed RP (Hansen and Olsen, 1989). Bleomycin, in
particular, appears to be the key player in the development of RP
in these patients. Indeed, findings of a recent large cross-sectional
study showed that the only significant predictor of persistent
RP at follow-up after chemotherapy was the bleomycin dose
(Glendenning et al., 2010).
TREATMENT OF RP
Significant efforts have been undertaken to better understand
and treat RP (Lee et al., 2014; Poredos and Poredos, 2016).
However, no definitive or specific therapy for this disease has
yet been approved by the U.S. Food and Drug Administration
(FDA; Landry, 2013). One of the limiting factors in the war
against this disease in the incomplete understanding of its
pathophysiology (Landry, 2013), which is further compounded
by the lack of appropriate animal models for RP. Moreover,
a treatment regimen efficacy may depend on the severity and
type of the disease, as well as on the degree of vascular
damage. Despite that, some medications or treatment options
that are thought to alleviate symptoms of the disease are being
employed in the clinic. These options can be collectively classified
into traditional pharmacological, ethno-pharmacological, non-
traditional treatments, and most recently surgical intervention
(Table 1).
Traditional pharmacological drugs alleviate RP symptoms
by reducing vasoconstriction, inducing vasodilatory effect, or
by a yet unclear mechanism. Drugs used for a vasodilatory
effect include calcium channel blockers, cyclic guanosine
monophosphate (cGMP)-specific phosphodiesterase type-5
(PDE5) inhibitors, prostacyclins, prostaglandin analogs, and
alpha-1 blockers. Calciumchannel blockers are the most common
and preferred first-line treatment (Halawa, 2001; Thompson
and Pope, 2005). However, in the most recent and highly
comprehensive Cochrane review where seven randomized trials
involving 296 patients were analyzed, it was concluded that
oral calcium channel blockers are relatively ineffective in the
treatment of primary RP. Authors of this important review
conclude that evidence does not support a role of these blockers
in reducing the frequency and severity of attacks (Ennis et al.,
2016). This is somewhat inconsistent with an earlier meta-
analysis which suggested some, albeit small, efficacy of these
blockers in reducing the severity of RP attacks (Thompson and
Pope, 2005). However, authors of this paper highlighted the
notion that most of the trials included in their meta-analysis were
crossover studies that did not determine order effect, thus likely
introducing some bias (Thompson and Pope, 2005). cGMP-
specific PDE5 inhibitors have been used as well (Caglayan et al.,
2006). Indeed, in an open-label pilot study involving 40 patients,
it was found that digital flow was significantly improved in RP
patients receiving the PDE V inhibitor, vardenafil, treatment
(Caglayan et al., 2006). Consistently with this, it was also found
that PDE5 inhibitors decrease vasospastic attacks and improve
digital blood flow (Lee et al., 2014). Indeed, this efficacy of
PDE5 inhibitor was reported in a double-blind, randomized,
cross-over study involving 29 patients that were divided into two
groups. One group received udenafil, a PDE V inhibitor, and
the other a calcium channel blocker, amlodipine, over a period
of 4 weeks. Both treatments showed comparable efficacy in RP
treatment in regard to decreasing the severity of vasospastic
attacks (Lee et al., 2014). In addition, patients receiving the PDE
V inhibitor showed better digital blood flow when compared to
those receiving amlodipine (Lee et al., 2014).
Prostanoids are reported to decrease the severity and
frequency of vasospastic attacks in RP patients. Their efficacy
has been consistently reported in systematic reviews, meta-
analyses as well as in multiple randomized clinical trials (Clifford
et al., 1980; Mohrland et al., 1985; Wigley et al., 1994; Pope
et al., 2000; Scorza et al., 2001; Milio et al., 2006; Kawald
et al., 2008). For instance, iloprost, a prostacyclin analog was
used to treat 13 patients with RP. In addition to reducing
ulcerating lesions, iloprost also caused improvement in blood
flow in these patients (Rademaker et al., 1987). Moreover,
in a double-blind placebo-controlled trial, it was found that
buflomedil causes a reduction in the frequency of attacks,
but with no effect on Raynaud severity score (Le Quentrec
and Lefebvre, 1991). On the other hand, a Cochrane review
concluded that evidence does not support a benefit for beraprost,
ketanserin, dazoxiben, and moxisylyte in ameliorating frequency
duration or severity of attacks (Stewart and Morling, 2012).
However, the authors of this review indicated that the precision
of their conclusion is affected by the fact that most of
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TABLE 1 | Various lines of treatment of Raynaud’s disease.
Treatment Effectiveness Reference
Traditional treatment Calcium channel blockers Effective; first-line of treatment Halawa, 2001; Thompson and Pope, 2005
PTK inhibitors Efficient Furspan et al., 2004, 2005
PDE5 inhibitors Inefficient Lee et al., 2014
Beta-blockers Controversial Marshall et al., 1976Koltringer et al., 1991
Statins Emerging/powerful Abou-Raya et al., 2008
Prostacyclins Efficient Rademaker et al., 1987
ACE inhibitors Variable effect Henness and Wigley, 2007
Endothelin receptor antagonists Variable effect Poredos and Poredos, 2016
Serotonin receptor antagonists Effective Coleiro et al., 2001
Non-Traditional treatment Botulinum toxin type A Efficient Neumeister et al., 2014
Chinese herb Ineffective Wu et al., 2008
Ginkgo biloba Ineffective Muir et al., 2002
Acupuncture Efficient Appiah et al., 1997
Laser therapy Efficient Hirschl et al., 2004
Surgery Thoracic sympathectomy Effective Coveliers et al., 2011
Hand stripping Effective Balogh et al., 2002
Nerve stimulation effective Kaada, 1982
Fat grafting Encouraging results Bank et al., 2014
A summary of the traditional and non-traditional therapies, as well as some surgical interventions.
the studies included in their review are poorly designed or
executed
Angiotensin receptor blockers, ACE (Angiotensin Converting
Enzyme) inhibitors, PTK (protein tyrosine kinase) inhibitors,
and endothelin receptor antagonists (ETRAs) are also employed
in the treatment of RP owing to their ability to reduce
vasoconstriction. A clinical trial reported that losartan (50 mg)
causes a significant reduction in the severity and frequency of
spastic episodes (Dziadzio et al., 1999). The therapeutic benefit
of using ACE inhibitors in the management of RP seems to be
variable (Henness and Wigley, 2007). Some studies have reported
that they may have minor benefits, albeit to a lesser extent than
traditional therapies (Wood and Ernst, 2006). Indeed, it is not
recommended that angiotensin receptor blockers be replaces with
ACE inhibitors for the treatment of RP (Linnemann and Erbe,
2016). It is important to note here that although enalapril and
captopril are reported to reduce the number of attacks in primary
RP, they do not appear to be effective in reducing these attacks
in secondary RP (Tosi et al., 1987; Janini et al., 1988). Moreover,
in a multicenter, randomized, double-blind, placebo-controlled
trial involving 210 patients, quinapril treatment for up to 3 years
did not show any beneficial effects in reducing the severity
of frequency of attacks (Gliddon et al., 2007). The increased
phosphorylation of PTK is associated with the α2C-AR-mediated
vasoconstriction, thus PTK inhibitors may be used to reverse the
contractile response to cooling, as these studies show that PTK
phosphorylation is higher in RP patients arterioles in comparison
to ctrl arterioles (Furspan et al., 2004, 2005). However, future
studies must be done on this interesting type of treatment.
One of the early events thought to play a role in the
vasculopathy of scleroderma is endothelial injury. Because such
injury leads to increased release of the potent vasoconstrictor,
endothlin-1, it was thought that blocking endothelin signaling
and function could play a beneficial role in the treatment
of systemic scleroderma (SSc) and the associated secondary
RP. When ETRAs were employed, not all patients responded
positively; nonetheless, these antagonists were able to at least
alleviate the severity and frequency of vasospastic attacks
(Poredos and Poredos, 2016). Several studies have looked at
the effect of ETRAs in the treatment of SSc-associated RP.
In 2006, the first prospective study investigating the potential
benefit of ETRAs in RP was published (Selenko-Gebauer et al.,
2006). The patients involved in this study received bosentan
for 16-week, after which it was found that severity of RP
attacks was significantly reduced. Another observational study
also reported that after a median of 8 weeks of treatment with
bosentan, severity of RP was also reduced (Funauchi et al.,
2009). Whether beta blockers have a therapeutic value remains
controversial. One studies involving 102 patients report that the
beta blockers Propranolol, Oxprenolol, and Atenolol disturb the
microcirculation causing RP as a side effect (Marshall et al., 1976).
Consistent with this, a meta-analysis of 13 studies suggests that
the use of beta blockers is associated with higher incidence of RP
(Mohokum et al., 2012). On the other hand, other reports suggest
that beta blockers could be beneficial particularly because of their
ability to reduce blood viscosity (Koltringer et al., 1991). In this
study, half of the 40 participants involved received metoprolol,
and showed reduced blood viscosity compared to the control
group. Interestingly, a combination treatment of beta blockers
(metoprolol) with calcium channel inhibitors (felodipin) was
shown to be very effective in reducing symptoms of RP (Csiki
et al., 2011).
There are other drugs that appear to have a potential for use
in the management of RP. These include statins (Abou-Raya
et al., 2008) and serotonin receptor antagonists (Coleiro et al.,
2001). Although their mechanism of action is not fully clear, they
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appear to retard vascular injury, lessen severity, and reduce pain
associated with RP.
A recent report discussed the potential benefit of using a rather
non-traditional approach for the treatment of RP. Botulinum
toxin type A (BTX-A) can be locally injected to improve ulcerated
digits and alleviate the associated pain (Neumeister et al., 2014).
This improvement may be due to better perfusion and improved
vascularity; however, the exact mechanism remains unknown.
Notably, studies have shown that the use of BTX-A could
be safe and efficient (Neumeister et al., 2014). In a recent
retrospective study, it was shown that local injection of BTX-
A provides great improvement in artery flow velocity, surface
temperature, ulcer, and other clinical symptoms (as measured by
visual analog scale; Zhang et al., 2015). Others have also reported
similar beneficial effects of BTX-A in the management of RP
(Smith et al., 2012; Zhao and Lian, 2015). However, despite all
these interesting and promising results, a recent systemic review
concludes that evidence to support the efficacy of BTX-A in
the management of RP remains insufficient. As such, further
research, particularly randomized controlled trials, is needed
to better determine the potential efficacy of this interesting
approach.
It is worth mentioning that in some patients, the
aforementioned pharmacological drugs may cause several
side effects such as headaches and dizziness. As such, many
patients resort to alternative therapies in the hope of avoiding
such undesired side effects. Herbal therapies are one common
approach. Of particular interest in the management of RP is
Ginkgo biloba plant extracts (Muir et al., 2002) or a combination
of two Chinese herbal medications, Duhuo-Tisheng Tang and
Danggui-Sini Tang (Wu et al., 2008). However, contradictory
reports suggest that that digital vascular response of RP patients
receiving this therapy was not changed in patients consuming
the above herbal combination (Appiah et al., 1997; Hirschl et al.,
2004; Wu et al., 2008). Acupuncture has also be employed in the
management of RP. Indeed, a randomized controlled prospective
study concluded that traditional Chinese acupuncture appears
to be an effective approach in relieving symptoms, particularly
attack frequency, of primary RP (Appiah et al., 1997). Others
have also reported that auricular electroacupuncture could
be helpful in reducing severity and frequency of RP attacks
(Schlager et al., 2011). However, meta-analysis and systematic
review of the literature does not conclusively support the use of
acupuncture in the management of RP (Malenfant et al., 2009;
Huisstede et al., 2011).
Laser therapy has also received some attention. A randomized
placebo-controlled double-blind crossover study involving 48
patients shows that low level laser therapy could reduce frequency
and severity of RP attacks (Hirschl et al., 2004). Findings of this
study are consistent with those of another double-blind study
that appeared in the same year (al-Awami et al., 2004). High-
peak power laser treatment has also been reported to reduce
the frequency and severity of attacks in a patient suffering from
Scleroderma and RP (St Surin-Lord and Obagi, 2011).
It is important to note that surgical therapies may be
considered as an option of treatment (Landry, 2013). These
therapies include thoracic sympathectomy, hand stripping, and
nerve stimulation (Kaada, 1982; Balogh et al., 2002; Coveliers
et al., 2011). Although invasive, these are considered to be
successful in pain reduction and ulcer healing (Landry, 2013).
Finally, fat grafting in the patient’s hands is a new and
rather unconventional surgical therapy for RP patients (Bank
et al., 2014). This novel treatment originated from clinical
improvements observed after fat grafting in hands suffering
from burns and radiation dermatitis (Rigotti et al., 2007). When
it was later “tested” on a group of RP patients, the results
were encouraging and included alleviation of pain, decrease of
ulcers, and decline in cold attacks (Bank et al., 2014). Although
the mechanism by which fat grafting caused these effects is
largely unclear, it is hypothesized that pathways involving
neoangiogenesis and stem cells are likely implicated (Bank et al.,
2014).
The variability of the treatments and their altered efficacies
calls for urgent and concerted efforts to better understand the
molecular mechanisms underlying the disease, as well as to
develop more targeted and efficient drugs. These drugs may
include blockers of α2−ARs as well as inhibitors of PTKs and
Rho kinase (Lambova and Muller-Ladner, 2009). Indeed, the first
proof of concept for ameliorating RP attacks by blocking α2-
ARs came from a study by Freedman et al. (1995). This paper
showed that yohimbine, α2-AR antagonist, but not prazosin,
α1-AR antagonist, can significantly attenuate vasospastic attacks
of RP. More specifically, a double-blind, placebo-controlled,
randomized crossover study investigated the efficacy of OPC-
28326, a selective α-AR antagonist with preferential binding to
the α2C-AR subtype, in recovery from cold-induced vasospasm
in secondary RP patients. This study showed that OPC-28326
is able to improve digital blood flow after acute cold challenge
in patients with RP secondary to scleroderma (Wise et al.,
2004). Another phase II, randomized, double-blind, crossover,
single-dose, placebo-controlled, study also tested the efficacy
of ORM-12741, a potent α2C-AR antagonist. Interestingly,
findings of this study were unexpected in that ORM-12741
prolonged, rather than shortened, the duration of the cold-
induced constriction of digital arteries evident by delayed
rewarming after a cold challenge (Herrick et al., 2014). The
reasons for this rather unexpected result remain unclear and
thus, further research is warranted to better understand the
intriguing biology of α2C-AR especially as it related to RP
pathophysiology.
CONCLUSION AND PERSPECTIVES
Despite the exponentially growing research and biomedical
advances, a definitive and curative treatment for RP still poses
a real and elusive challenge. Although many aspects and factors
contributing to this disease have been dissected, the molecular
mechanisms underlying the onset and progression of RP still
require further investigations. This is, in no small part, due to the
multifactorial etiology (hormonal, neuronal, and endothelial) of
the disease. Another challenge is the absence of an appropriate
animal model of the disease. The fact that α2C-AR is expressed
in many brain regions such as the olfactory bulb and the cerebral
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cortex further complicates the hunt for an RP-specific drug. This
is especially challenging because α2C-ARs are also implicated
in presynaptic regulation of the heart. Thus, targeting α2C-ARs
in an attempt to treat RP would not be most suitable, since it
will affect the heart and brain as well. However, it is tempting
to speculate that applying topical creams containing α2C-ARs
blockers to affected body parts could be beneficial, and likely with
fewer side effects. However, rigorous basic research and clinical
trials are needed to support this suggestion. So far, precaution is
often effective in reducing cold-induced vasospastic attacks of RP.
AUTHOR CONTRIBUTIONS
All authors contributed to the writing. AHE conceived, designed,
and revised the manuscript.
ACKNOWLEDGMENT
The authors would like to thank Ms. Tuqa Saleh Al-Shehabi for
her assistance in drawing the figures.
REFERENCES
Abou-Raya, A., Abou-Raya, S., and Helmii, M. (2008). Statins: potentially useful in
therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers.
J. Rheumatol. 35, 1801–1808.
Ahles, A., and Engelhardt, S. (2014). Polymorphic variants of adrenoceptors:
pharmacology, physiology, and role in disease. Pharmacol. Rev. 66, 598–637.
doi: 10.1124/pr.113.008219
al-Awami, M., Schillinger, M., Maca, T., Pollanz, S., and Minar, E. (2004). Low level
laser therapy for treatment of primary and secondary Raynaud’s phenomenon.
Vasa 33, 25–29. doi: 10.1024/0301-1526.33.1.25
Anderson, J. E., Held, N., and Wright, K. (2004). Raynaud’s phenomenon of the
nipple: a treatable cause of painful breastfeeding. Pediatrics 113, e360–e364. doi:
10.1542/peds.113.4.e360
Appiah, R., Hiller, S., Caspary, L., Alexander, K., and Creutzig, A.
(1997). Treatment of primary Raynaud’s syndrome with traditional
Chinese acupuncture. J. Intern. Med. 241, 119–124. doi: 10.1046/j.1365-
2796.1997.91105000.x
Bailey, S. R., Eid, A. H., Mitra, S., Flavahan, S., and Flavahan, N. A.
(2004). Rho kinase mediates cold-induced constriction of cutaneous arteries:
role of alpha2C-adrenoceptor translocation. Circ. Res. 94, 1367–1374. doi:
10.1161/01.RES.0000128407.45014.58
Bailey, S. R., Mitra, S., Flavahan, S., and Flavahan, N. A. (2005). Reactive oxygen
species from smooth muscle mitochondria initiate cold-induced constriction of
cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 289, H243–H250. doi:
10.1152/ajpheart.01305.2004
Balogh, B., Mayer, W., Vesely, M., Mayer, S., Partsch, H., and Piza-Katzer, H.
(2002). Adventitial stripping of the radial and ulnar arteries in Raynaud’s
disease. J. Hand Surg Am 27, 1073–1080. doi: 10.1053/jhsu.2002.35887
Bank, J., Fuller, S. M., Henry, G. I., and Zachary, L. S. (2014). Fat grafting to the
hand in patients with Raynaud phenomenon: a novel therapeutic modality.
Plast Reconstr. Surg. 133, 1109–1118. doi: 10.1097/PRS.0000000000000104
Belch, J. J. F., and Ho, M. (2001). “Vasospastic disorders and vasculitis,” in Vascular
and Endovascular Surgery, eds J. D. Beard and P. A. Gaines (London: WB
Saunders and Company), 217–240.
Black, C. M. (1995). Systemic sclerosis ‘state of the art’ 1995. Scand. J. Rheumatol.
24, 194–196. doi: 10.3109/03009749509100872
Block, J. A., and Sequeira, W. (2001). Raynaud’s phenomenon. Lancet 357,
2042–2048. doi: 10.1016/S0140-6736(00)05118-7
Caglayan, E., Huntgeburth, M., Karasch, T., Weihrauch, J., Hunzelmann, N.,
Krieg, T., et al. (2006). Phosphodiesterase type 5 inhibition is a novel
therapeutic option in Raynaud disease. Arch. Intern. Med. 166, 231–233. doi:
10.1001/archinte.166.2.231
Cardelli, M. B., and Kleinsmith, D. M. (1989). Raynaud’s phenomenon and disease.
Med. Clin. North Am. 73, 1127–1141. doi: 10.1016/S0025-7125(16)30623-X
Carmichael, J. (1998). The role of gemcitabine in the treatment of other tumours.
Br. J. Cancer 78(Suppl. 3), 21–25. doi: 10.1038/bjc.1998.750
Chan, N. N., MacAllister, R. J., Colhoun, H. M., Vallance, P., and Hingorani,
A. D. (2001). Changes in endothelium-dependent vasodilatation and alpha-
adrenergic responses in resistance vessels during the menstrual cycle in healthy
women. J. Clin. Endocrinol. Metab. 86, 2499–2504. doi: 10.1210/jcem.86.6.
7581
Chant, A. D. (1987). Exaggerated postural vasoconstrictor reflex in Raynaud’s
phenomenon. Br.Med. J. (Clin. Res. Ed.) 295:51. doi: 10.1136/bmj.295.6589.51-a
Charkoudian, N. (2010). Mechanisms and modifiers of reflex induced cutaneous
vasodilation and vasoconstriction in humans. J. Appl. Physiol. (1985) 109,
1221–1228. doi: 10.1152/japplphysiol.00298.2010
Charkoudian, N., and Stachenfeld, N. (2016). Sex hormone effects on autonomic
mechanisms of thermoregulation in humans. Auton. Neurosci. 196, 75–80. doi:
10.1016/j.autneu.2015.11.004
Cherniack, M., Clive, J., and Seidner, A. (2000). Vibration exposure, smoking,
and vascular dysfunction. Occup. Environ. Med. 57, 341–347. doi:
10.1136/oem.57.5.341
Chitaley, K., and Webb, R. C. (2002). Microtubule depolymerization facilitates
contraction of rat aorta via activation of Rho-kinase. Vascul. Pharmacol. 38,
157–161. doi: 10.1016/S1537-1891(02)00163-5
Chotani, M. A., Flavahan, S., Mitra, S., Daunt, D., and Flavahan, N. A. (2000).
Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in
cutaneous arteries. Am. J. Physiol. Heart Circ. Physiol. 278, H1075–H1083.
Chotani, M. A., Mitra, S., Su, B. Y., Flavahan, S., Eid, A. H., Clark, K. R.,
et al. (2004). Regulation of alpha(2)-adrenoceptors in human vascular smooth
muscle cells. Am. J. Physiol. Heart Circ. Physiol. 286, H59–H67. doi:
10.1152/ajpheart.00268.2003
Clifford, P. C., Martin, M. F., Sheddon, E. J., Kirby, J. D., Baird, R. N., and Dieppe,
P. A. (1980). Treatment of vasospastic disease with prostaglandin E1. Br. Med.
J. 281, 1031–1034. doi: 10.1136/bmj.281.6247.1031
Clowse, M. E., and Wigley, F. M. (2003). Digital necrosis related to carboplatin and
gemcitabine therapy in systemic sclerosis. J. Rheumatol. 30, 1341–1343.
Coleiro, B., Marshall, S. E., Denton, C. P., Howell, K., Blann, A., Welsh, K. I.,
et al. (2001). Treatment of Raynaud’s phenomenon with the selective serotonin
reuptake inhibitor fluoxetine. Rheumatology (Oxford) 40, 1038–1043. doi:
10.1093/rheumatology/40.9.1038
Coveliers, H. M., Hoexum, F., Nederhoed, J. H., Wisselink, W., and Rauwerda, J. A.
(2011). Thoracic sympathectomy for digital ischemia: a summary of evidence.
J. Vasc. Surg. 54, 273–277. doi: 10.1016/j.jvs.2011.01.069
Coward, J., Maisey, N., and Cunningham, D. (2005). The effects of capecitabine
in Raynaud’s disease: a case report. Ann. Oncol. 16, 835–836. doi:
10.1093/annonc/mdi144
Csiki, Z., Garai, I., Shemirani, A. H., Papp, G., Zsori, K. S., Andras, C., et al.
(2011). The effect of metoprolol alone and combined metoprolol-felodipin
on the digital microcirculation of patients with primary Raynaud’s syndrome.
Microvasc. Res. 82, 84–87. doi: 10.1016/j.mvr.2011.04.004
D’Alessandro, V., Errico, M., Varriale, A., Greco, A., De Cata, A., Carnevale, V.,
et al. (2003). [Case report: Acro-necrosis of the upper limbs caused by
gemcitabine therapy]. Clin. Ter. 154, 207–210.
Dziadzio, M., Denton, C. P., Smith, R., Howell, K., Blann, A., Bowers, E.,
et al. (1999). Losartan therapy for Raynaud’s phenomenon and scleroderma:
clinical and biochemical findings in a fifteen-week, randomized, parallel-
group, controlled trial. Arthritis Rheum. 42, 2646–2655. doi: 10.1002/1529-
0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T
Easter, M. J., and Marshall, J. M. (2005). Contribution of prostanoids to
endothelium-dependent vasodilatation in the digital circulation of women
with primary Raynaud’s disease. Clin. Sci. (Lond). 109, 45–54. doi:
10.1042/CS20040262
Eid, A. H., Chotani, M. A., Mitra, S., Miller, T. J., and Flavahan, N. A. (2008). Cyclic
AMP acts through Rap1 and JNK signaling to increase expression of cutaneous
smooth muscle alpha2C-adrenoceptors. Am. J. Physiol. Heart Circ. Physiol. 295,
H266–H272. doi: 10.1152/ajpheart.00084.2008
Frontiers in Pharmacology | www.frontiersin.org 10 November 2016 | Volume 7 | Article 438
fphar-07-00438 November 14, 2016 Time: 16:2 # 11
Fardoun et al. Raynaud’s Phenomenon
Eid, A. H., Maiti, K., Mitra, S., Chotani, M. A., Flavahan, S., Bailey,
S. R., et al. (2007). Estrogen increases smooth muscle expression of
alpha2C-adrenoceptors and cold-induced constriction of cutaneous
arteries. Am. J. Physiol. Heart Circ. Physiol. 293, H1955–H1961. doi:
10.1152/ajpheart.00306.2007
English, K. M., Jones, R. D., Jones, T. H., Morice, A. H., and Channer, K. S. (2001).
Gender differences in the vasomotor effects of different steroid hormones in
rat pulmonary and coronary arteries. Horm. Metab. Res. 33, 645–652. doi:
10.1055/s-2001-18689
Ennis, H., Hughes, M., Anderson, M. E., Wilkinson, J., and Herrick, A. L.
(2016). Calcium channel blockers for primary Raynaud’s phenomenon.
Cochrane Database Syst. Rev. 2: CD002069. doi: 10.1002/14651858.CD002069.
pub5
Falappa, P., Magnavita, N., Bergamaschi, A., and Colavita, N. (1982). Angiographic
study of digital arteries in workers exposed to vinyl chloride. Br. J. Ind. Med. 39,
169–172.
Flavahan, N. A. (2015). A vascular mechanistic approach to understanding
Raynaud phenomenon. Nat. Rev. Rheumatol. 11, 146–158. doi:
10.1038/nrrheum.2014.195
Fletcher, D. A., and Mullins, R. D. (2010). Cell mechanics and the cytoskeleton.
Nature 463, 485–492. doi: 10.1038/nature08908
Fontana, L., Marion, M. J., Ughetto, S., and Catilina, P. (2006). Glutathione
S-transferase M1 and GST T1 genetic polymorphisms and Raynaud’s
phenomenon in French vinyl chloride monomer-exposed workers. J. Hum.
Genet. 51, 879–886. doi: 10.1007/s10038-006-0038-9
Fraenkel, L., Zhang, Y., Chaisson, C. E., Evans, S. R., Wilson, P. W., and Felson,
D. T. (1998). The association of estrogen replacement therapy and the Raynaud
phenomenon in postmenopausal women. Ann. Intern. Med. 129, 208–211. doi:
10.7326/0003-4819-129-3-199808010-00009
Freedman, R. R., Baer, R. P., and Mayes, M. D. (1995). Blockade of
vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic
antagonists in idiopathic Raynaud’s disease. Circulation 92, 1448–1451. doi:
10.1161/01.CIR.92.6.1448
Freedman, R. R., Moten, M., Migaly, P., and Mayes, M. (1993). Cold-induced
potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud’s
disease. Arthritis Rheum. 36, 685–690. doi: 10.1002/art.1780360517
Freedman, R. R., Sabharwal, S. C., Moten, M., and Migaly, P. (1992). Local
temperature modulates alpha 1- and alpha 2-adrenergic vasoconstriction in
men. Am. J. Physiol. 263, H1197–H1200.
Funauchi, M., Kishimoto, K., Shimazu, H., Nagare, Y., Hino, S., Yano, T., et al.
(2009). Effects of bosentan on the skin lesions: an observational study from a
single center in Japan. Rheumatol. Int. 29, 769–775. doi: 10.1007/s00296-008-
0789-z
Furspan, P. B., Chatterjee, S., and Freedman, R. R. (2004). Increased tyrosine
phosphorylation mediates the cooling-induced contraction and increased
vascular reactivity of Raynaud’s disease. Arthritis Rheum. 50, 1578–1585. doi:
10.1002/art.20214
Furspan, P. B., Chatterjee, S., Mayes, M. D., and Freedman, R. R. (2005).
Cooling-induced contraction and protein tyrosine kinase activity of isolated
arterioles in secondary Raynaud’s phenomenon. Rheumatology 44, 488–494.
doi: 10.1093/rheumatology/keh517
Garner, R., Kumari, R., Lanyon, P., Doherty, M., and Zhang, W. (2015). Prevalence,
risk factors and associations of primary Raynaud’s phenomenon: systematic
review and meta-analysis of observational studies. BMJ Open 5: e006389. doi:
10.1136/bmjopen-2014-006389
Gentric, A., Blaschek, M. A., Le Noach, J. F., Johanet, C., Jouquan, J., Lamour, A.,
et al. (1990). Serological arguments for classifying Raynaud’s phenomenon as
idiopathic. J. Rheumatol. 17, 1177–1181.
Gerbracht, D. D., Steen, V. D., Ziegler, G. L., Medsger, T. A. Jr., and Rodnan,
G. P. (1985). Evolution of primary Raynaud’s phenomenon (Raynaud’s
disease) to connective tissue disease. Arthritis Rheum. 28, 87–92. doi:
10.1002/art.1780280114
Glendenning, J. L., Barbachano, Y., Norman, A. R., Dearnaley, D. P., Horwich, A.,
and Huddart, R. A. (2010). Long-term neurologic and peripheral vascular
toxicity after chemotherapy treatment of testicular cancer. Cancer 116,
2322–2331. doi: 10.1002/cncr.24981
Gliddon, A. E., Dore, C. J., Black, C. M., McHugh, N., Moots, R., Denton, C. P.,
et al. (2007). Prevention of vascular damage in scleroderma and autoimmune
Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-
controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
Arthritis Rheum. 56, 3837–3846. doi: 10.1002/art.22965
Gottschling, S., Meyer, S., Reinhard, H., Krenn, T., and Graf, N. (2004). First
report of a vincristine dose-related Raynaud’s phenomenon in an adolescent
with malignant brain tumor. J. Pediatr. Hematol. Oncol. 26, 768–769. doi:
10.1097/00043426-200411000-00017
Greenstein, D., Jeffcote, N., Ilsley, D., and Kester, R. C. (1996). The
menstrual cycle and Raynaud’s phenomenon. Angiology 47, 427–436. doi:
10.1177/000331979604700501
Guimaraes, S., and Moura, D. (2001). Vascular adrenoceptors: an update.
Pharmacol. Rev. 53, 319–356.
Halawa, B. (2001). [Calcium channel blockers in the treatment of cardiovascular
disease]. Pol. Merkur. Lekarski 11, 83–87.
Hall, A. (1998). Rho GTPases and the actin cytoskeleton. Science 279, 509–514. doi:
10.1126/science.279.5350.509
Hall, A. H. (2002). Chronic arsenic poisoning. Toxicol. Lett. 128, 69–72. doi:
10.1016/S0378-4274(01)00534-3
Hansen, S. W., and Olsen, N. (1989). Raynaud’s phenomenon in patients treated
with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of
vasoconstrictor response to cold. J. Clin. Oncol. 7, 940–942.
Heidrich, H. (2010). Functional vascular diseases: Raynaud’s syndrome,
acrocyanosis and erythromelalgia. Vasa 39, 33–41. doi: 10.1024/0301-
1526/a000003
Henness, S., and Wigley, F. M. (2007). Current drug therapy for scleroderma
and secondary Raynaud’s phenomenon: evidence-based review. Curr. Opin.
Rheumatol. 19, 611–618. doi: 10.1097/BOR.0b013e3282f13137
Herrick, A. L. (2012). The pathogenesis, diagnosis and treatment of Raynaud
phenomenon. Nat. Rev. Rheumatol. 8, 469–479. doi: 10.1038/nrrheum.2012.96
Herrick, A. L., Murray, A. K., Ruck, A., Rouru, J., Moore, T. L., Whiteside, J.,
et al. (2014). A double-blind, randomized, placebo-controlled crossover trial
of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-
induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford)
53, 948–952. doi: 10.1093/rheumatology/ket421
Hirschl, M., Katzenschlager, R., Francesconi, C., and Kundi, M. (2004). Low
level laser therapy in primary Raynaud’s phenomenon–results of a placebo
controlled, double blind intervention study. J. Rheumatol. 31, 2408–2412.
Holstein, A., Batge, R., and Egberts, E. H. (2010). Gemcitabine induced digital
ischaemia and necrosis. Eur. J. Cancer Care (Engl). 19, 408–409. doi:
10.1111/j.1365-2354.2008.01057.x
Huisstede, B. M., Hoogvliet, P., Paulis, W. D., van Middelkoop, M., Hausman, M.,
Coert, J. H., et al. (2011). Effectiveness of interventions for secondary Raynaud’s
phenomenon: a systematic review.Arch. Phys.Med. Rehabil. 92, 1166–1180. doi:
10.1016/j.apmr.2011.01.022
Hurt, C. M., Feng, F. Y., and Kobilka, B. (2000). Cell-type specific targeting
of the alpha 2c-adrenoceptor. Evidence for the organization of receptor
microdomains during neuronal differentiation of PC12 cells. J. Biol. Chem. 275,
35424–35431. doi: 10.1074/jbc.M006241200
Jackson, C. M. (2006). The patient with cold hands: understanding Raynaud’s
disease. JAAPA 19, 34–38.
Janini, S. D., Scott, D. G., Coppock, J. S., Bacon, P. A., and Kendall, M. J. (1988).
Enalapril in Raynaud’s phenomenon. J. Clin. Pharm. Ther. 13, 145–150. doi:
10.1111/j.1365-2710.1988.tb00171.x
Jeyaraj, S. C., Chotani, M. A., Mitra, S., Gregg, H. E., Flavahan, N. A., and Morrison,
K. J. (2001). Cooling evokes redistribution of alpha2C-adrenoceptors from
Golgi to plasma membrane in transfected human embryonic kidney 293 cells.
Mol. Pharmacol. 60, 1195–1200.
Jeyaraj, S. C., Unger, N. T., Eid, A. H., Mitra, S., Paul El-Dahdah, N., Quilliam,
L. A., et al. (2012). Cyclic AMP-Rap1A signaling activates RhoA to induce
alpha(2c)-adrenoceptor translocation to the cell surface of microvascular
smooth muscle cells. Am. J. Physiol. Cell Physiol. 303, C499–C511. doi:
10.1152/ajpcell.00461.2011
Johnson, J. M., and Kellogg, D. L. Jr. (2010). Local thermal control of the
human cutaneous circulation. J. Appl. Physiol. (1985) 109, 1229–1238. doi:
10.1152/japplphysiol.00407.2010
Kaada, B. (1982). Vasodilation induced by transcutaneous nerve stimulation in
peripheral ischemia (Raynaud’s phenomenon and diabetic polyneuropathy).
Eur. Heart J. 3, 303–314.
Frontiers in Pharmacology | www.frontiersin.org 11 November 2016 | Volume 7 | Article 438
fphar-07-00438 November 14, 2016 Time: 16:2 # 12
Fardoun et al. Raynaud’s Phenomenon
Kawald, A., Burmester, G. R., Huscher, D., Sunderkotter, C., and Riemekasten, G.
(2008). Low versus high-dose iloprost therapy over 21 days in patients with
secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open,
single-center study. J. Rheumatol. 35, 1830–1837.
Koltringer, P., Langsteger, W., Pierer, G., Lind, P., Klima, G., Reisecker, F., et al.
(1991). [Effect of metoprolol on microcirculation and blood viscoelasticity].
Acta Med. Austriaca 18, 75–77.
Kristensen, J. K. (1979). Local regulation of digital blood flow in
generalized scleroderma. J. Invest. Dermatol. 72, 235–240. doi:
10.1111/1523-1747.ep12531698
Kuhar, C. G., Mesti, T., and Zakotnik, B. (2010). Digital ischemic events related
to gemcitabine: report of two cases and a systematic review. Radiol. Oncol. 44,
257–261. doi: 10.2478/v10019-010-0020-1
Kundu, D., Abraham, D., Black, C. M., Denton, C. P., and Bruckdorfer, K. R.
(2014). Reduced levels of S-nitrosothiols in plasma of patients with systemic
sclerosis and Raynaud’s phenomenon. Vascul. Pharmacol. 63, 178–181. doi:
10.1016/j.vph.2014.09.003
Lagerkvist, B., Linderholm, H., and Nordberg, G. F. (1986). Vasospastic tendency
and Raynaud’s phenomenon in smelter workers exposed to arsenic. Environ.
Res. 39, 465–474. doi: 10.1016/S0013-9351(86)80070-6
Lambova, S. N., and Muller-Ladner, U. (2009). New lines in therapy of Raynaud’s
phenomenon. Rheumatol. Int. 29, 355–363. doi: 10.1007/s00296-008-0792-4
Landry, G. J. (2013). Current medical and surgical management of Raynaud’s
syndrome. J. Vasc. Surg. 57, 1710–1716. doi: 10.1016/j.jvs.2013.03.012
Le Quentrec, P., and Lefebvre, M. L. (1991). Double-blind placebo-controlled trial
of buflomedil in the treatment of Raynaud’s phenomenon: six-month follow-up.
Angiology 42, 289–295. doi: 10.1177/000331979104200405
Lee, E. Y., Park, J. K., Lee, W., Kim, Y. K., Park, C. S., Giles, J. T., et al.
(2014). Head-to-head comparison of udenafil vs amlodipine in the treatment
of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over
study. Rheumatology (Oxford) 53, 658–664. doi: 10.1093/rheumatology/ket417
Leppert, J., Aberg, H., Levin, K., and Ringqvist, I. (1990). Lower serum magnesium
level after exposure to cold in women with primary Raynaud’s phenomenon.
J. Intern. Med. 228, 235–239. doi: 10.1111/j.1365-2796.1990.tb00224.x
Li, T., Xiao, X., Zhang, J., Zhu, Y., Hu, Y., Zang, J., et al. (2014). Age
and sex differences in vascular responsiveness in healthy and trauma
patients: contribution of estrogen receptor-mediated Rho kinase and PKC
pathways. Am. J. Physiol. Heart Circ. Physiol. 306, H1105–H1115. doi:
10.1152/ajpheart.00645.2013
Linnemann, B., and Erbe, M. (2016). Raynaud’s phenomenon and digital
ischaemia–pharmacologic approach and alternative treatment options. Vasa
45, 201–212. doi: 10.1024/0301-1526/a000526
MacDonald, E., Kobilka, B. K., and Scheinin, M. (1997). Gene targeting–homing in
on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18, 211–219.
doi: 10.1016/S0165-6147(97)01063-8
Malenfant, D., Catton, M., and Pope, J. E. (2009). The efficacy of complementary
and alternative medicine in the treatment of Raynaud’s phenomenon: a
literature review and meta-analysis. Rheumatology (Oxford) 48, 791–795. doi:
10.1093/rheumatology/kep039
Maricq, H. R., Carpentier, P. H., Weinrich, M. C., Keil, J. E., Franco, A., Drouet, P.,
et al. (1993). Geographic variation in the prevalence of Raynaud’s phenomenon:
Charleston, SC, USA, vs Tarentaise, Savoie, France. J. Rheumatol. 20,
70–76.
Maricq, H. R., Darke, C. S., Archibald, R. M., and Leroy, E. C. (1978). In vivo
observations of skin capillaries in workers exposed to vinyl chloride. An
English-American comparison. Br. J. Ind. Med. 35, 1–7.
Maricq, H. R., Johnson, M. N., Whetstone, C. L., and LeRoy, E. C. (1976). Capillary
abnormalities in polyvinyl chloride production workers. Examination by in vivo
microscopy. JAMA 236, 1368–1371. doi: 10.1001/jama.236.12.1368
Marshall, A. J., Roberts, C. J., and Barritt, D. W. (1976). Raynaud’s phenomenon
as side effect of beta-blockers in hypertension. Br. Med. J. 1, 1498–1499. doi:
10.1136/bmj.1.6024.1498
Maverakis, E., Patel, F., Kronenberg, D. G., Chung, L., Fiorentino, D., Allanore, Y.,
et al. (2014). International consensus criteria for the diagnosis of Raynaud’s
phenomenon. J. Autoimmun. 4, 60–65. doi: 10.1016/j.jaut.2014.01.020
Mayes, M. D. (1999). Epidemiologic studies of environmental agents and systemic
autoimmune diseases. Environ. Health Perspect. 107(Suppl. 5), 743–748. doi:
10.2307/3434336
McCance, K. L., and Huether, S. E. (2013). Pathophysiology: The Biologic Basis for
Disease in Adults and Children. Amsterdam: Elsevier.
McNeill, A. M., Leslie, F. M., Krause, D. N., and Duckles, S. P. (1999). Gender
difference in levels of alpha2-adrenoceptor mRNA in the rat tail artery. Eur.
J. Pharmacol. 366, 233–236. doi: 10.1016/S0014-2999(98)00948-0
Milio, G., Corrado, E., Genova, C., Amato, C., Raimondi, F., Almasio, P. L., et al.
(2006). Iloprost treatment in patients with Raynaud’s phenomenon secondary
to systemic sclerosis and the quality of life: a new therapeutic protocol.
Rheumatology (Oxford) 45, 999–1004. doi: 10.1093/rheumatology/kel038
Mohokum, M., Hartmann, P., and Schlattmann, P. (2012). The association of
Raynaud syndrome with beta-blockers: a meta-analysis. Angiology 63, 535–540.
doi: 10.1177/0003319711432861
Mohrland, J. S., Porter, J. M., Smith, E. A., Belch, J., and Simms, M. H. (1985).
A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in
Raynaud’s syndrome. Ann. Rheum. Dis. 44, 754–760. doi: 10.1136/ard.44.
11.754
Motawea, H. K., Jeyaraj, S. C., Eid, A. H., Mitra, S., Unger, N. T., Ahmed, A. A.,
et al. (2013). Cyclic AMP-Rap1A signaling mediates cell surface translocation
of microvascular smooth muscle alpha2C-adrenoceptors through the actin-
binding protein filamin-2. Am. J. Physiol. Cell Physiol. 305, C829–C845. doi:
10.1152/ajpcell.00221.2012
Muir, A. H., Robb, R., McLaren, M., Daly, F., and Belch, J. J. (2002). The use of
Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial.
Vasc. Med. 7, 265–267. doi: 10.1191/1358863x02vm455oa
Neumeister, M. W., Webb, K. N., and Romanelli, M. (2014). Minimally invasive
treatment of Raynaud phenomenon: the role of botulinum type A. Hand Clin.
30, 17–24. doi: 10.1016/j.hcl.2013.09.006
Nordberg, G. F., Fowler, B. A., Nordberg, M., and Friberg, L. (2014). Handbook on
the Toxicology of Metals. Amsterdam: Academic Press.
Nyronen, T., Pihlavisto, M., Peltonen, J. M., Hoffren, A. M., Varis, M.,
Salminen, T., et al. (2001). Molecular mechanism for agonist-promoted
alpha(2A)-adrenoceptor activation by norepinephrine and epinephrine. Mol.
Pharmacol. 59, 1343–1354.
Olsen, N., Petring, O. U., and Rossing, N. (1987). Exaggerated postural
vasoconstrictor reflex in Raynaud’s phenomenon. Br. Med. J. (Clin. Res. Ed.)
294, 1186–1188. doi: 10.1136/bmj.294.6581.1186
Pawlowski, M., Saraswathi, S., Motawea, H. K., Chotani, M. A., and
Kloczkowski, A. (2014). In silico modeling of human alpha2C-
adrenoreceptor interaction with filamin-2. PLoS ONE 9:e103099. doi:
10.1371/journal.pone.0103099
Pistorius, M. A., Planchon, B., Schott, J. J., and Lemarec, H. (2006). [Heredity
and genetic aspects of Raynaud’s disease]. J. Mal. Vasc. 31, 10–15. doi:
10.1016/S0398-0499(06)76512-X
Polonia, J. J., Paiva, M. Q., and Guimaraes, S. (1985). Pharmacological
characterization of postsynaptic alpha-adrenoceptor subtypes in five different
dog arteries in-vitro. J. Pharm. Pharmacol. 37, 205–208. doi: 10.1111/j.2042-
7158.1985.tb05043.x
Pope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., et al.
(2000). Iloprost and cisaprost for Raynaud’s phenomenon in progressive
systemic sclerosis. Cochrane Database Syst. Rev. 2:CD000953. doi:
10.1002/14651858.CD000953
Poredos, P., and Poredos, P. (2016). Raynaud’s syndrome: a neglected disease. Int.
Angiol. 35, 117–121.
Prete, M., Fatone, M. C., Favoino, E., and Perosa, F. (2014). Raynaud’s
phenomenon: from molecular pathogenesis to therapy. Autoimmun. Rev. 13,
655–667. doi: 10.1016/j.autrev.2013.12.001
Rademaker, M., Thomas, R. H., Provost, G., Beacham, J. A., Cooke, E. D., and
Kirby, J. D. (1987). Prolonged increase in digital blood flow following iloprost
infusion in patients with systemic sclerosis. Postgrad. Med. J. 63, 617–620. doi:
10.1136/pgmj.63.742.617
Reslan, O. M., and Khalil, R. A. (2012). Vascular effects of estrogenic
menopausal hormone therapy. Rev. Recent Clin. Trials 7, 47–70. doi:
10.2174/157488712799363253
Rigotti, G., Marchi, A., Galie, M., Baroni, G., Benati, D., Krampera, M., et al.
(2007). Clinical treatment of radiotherapy tissue damage by lipoaspirate
transplant: a healing process mediated by adipose-derived adult stem
cells. Plast Reconstr. Surg. 119, 1409–1422;discussion1423–1404. doi:
10.1097/01.prs.0000256047.47909.71
Frontiers in Pharmacology | www.frontiersin.org 12 November 2016 | Volume 7 | Article 438
fphar-07-00438 November 14, 2016 Time: 16:2 # 13
Fardoun et al. Raynaud’s Phenomenon
Roustit, M., Khouri, C., Blaise, S., Villier, C., Carpentier, P., and Cracowski, J. L.
(2014). [Pharmacology of Raynaud’s phenomenon]. Therapie 69, 115–128. doi:
10.2515/therapie/2013068
Rychlik-Golema, W., Mastej, K., and Adamiec, R. (2006). The role of endothelin-1
and selected cytokines in the pathogenesis of Raynaud’s phenomenon associated
with systemic connective tissue diseases. Int. Angiol. 25, 221–227.
Saif, M. W., Agarwal, A., Hellinger, J., Park, D. J., and Volkmann, E. (2016).
Scleroderma in a patient on capecitabine: is this a variant of hand-foot
syndrome? Cureus 8:e663. doi: 10.7759/cureus.663
Sallinen, J., Link, R. E., Haapalinna, A., Viitamaa, T., Kulatunga, M., Sjoholm, B.,
et al. (1997). Genetic alteration of alpha 2C-adrenoceptor expression in
mice: influence on locomotor, hypothermic, and neurochemical effects of
dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol.
Pharmacol. 51, 36–46.
Schlager, O., Gschwandtner, M. E., Mlekusch, I., Herberg, K., Frohner, T.,
Schillinger, M., et al. (2011). Auricular electroacupuncture reduces frequency
and severity of Raynaud attacks. Wien. Klin. Wochenschr. 123, 112–116. doi:
10.1007/S00508-011-1531-5
Scorza, R., Caronni, M., Mascagni, B., Berruti, V., Bazzi, S., Micallef, E., et al.
(2001). Effects of long-term cyclic iloprost therapy in systemic sclerosis
with Raynaud’s phenomenon. A randomized, controlled study. Clin. Exp.
Rheumatol. 19, 503–508.
Selenko-Gebauer, N., Duschek, N., Minimair, G., Stingl, G., and Karlhofer, F.
(2006). Successful treatment of patients with severe secondary Raynaud’s
phenomenon with the endothelin receptor antagonist bosentan. Rheumatology
(Oxford) 45(Suppl. 3), iii45–iii48. doi: 10.1093/rheumatology/kel290
Sharathkumar, A. A., and Castillo-Caro, P. (2011). Primary Raynaud’s
phenomenon in an infant: a case report and review of literature. Pediatr.
Rheumatol. Online J. 9:16. doi: 10.1186/1546-0096-9-16
Smith, L., Polsky, D., and Franks, A. G. Jr. (2012). Botulinum toxin-A for
the treatment of Raynaud syndrome. Arch. Dermatol. 148, 426–428. doi:
10.1001/archdermatol.2011.1144
Spengler, M. I., Svetaz, M. J., Leroux, M. B., Leiva, M. L., and Bottai, H. M.
(2004). Association between capillaroscopy, haemorheological variables and
plasma proteins in patients bearing Raynaud’s phenomenon. Clin. Hemorheol.
Microcirc. 30, 17–24.
St Surin-Lord, S., and Obagi, S. (2011). Scleroderma and raynaud’s phenomenon
improve with high-peak power laser therapy: a case report. Dermatol. Surg. 37,
1531–1535. doi: 10.1111/j.1524-4725.2011.02093.x
Stewart, M., and Morling, J. R. (2012). Oral vasodilators for primary
Raynaud’s phenomenon. Cochrane Database Syst. Rev. 7:CD006687. doi:
10.1002/14651858.CD006687.pub3
Susol, E., MacGregor, A. J., Barrett, J. H., Wilson, H., Black, C., Welsh, K., et al.
(2000). A two-stage, genome-wide screen for susceptibility loci in primary
Raynaud’s phenomenon. Arthritis Rheum. 43, 1641–1646. doi: 10.1002/1529-
0131(200007)43:7<1641::AID-ANR30>3.0.CO;2-Y
Tan, F. K., and Arnett, F. C. (2000). Genetic factors in the etiology of systemic
sclerosis and Raynaud phenomenon. Curr. Opin. Rheumatol. 12, 511–519. doi:
10.1097/00002281-200011000-00007
Thompson, A. E., and Pope, J. E. (2005). Calcium channel blockers for primary
Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford) 44, 145–150.
doi: 10.1093/rheumatology/keh390
Tosi, S., Marchesoni, A., Messina, K., Bellintani, C., Sironi, G., and Faravelli, C.
(1987). Treatment of Raynaud’s phenomenon with captopril. Drugs Exp. Clin.
Res. 13, 37–42.
Vanhoutte, P. M. (1980). “Physical factors and regulation of vascular smooth
muscle function,” in Handbook of Physiology, eds D. F. Bohr, A. P. Somlyo, and
H. V. Sparks (Washington, DC: The American Physiological Society), 443–474.
Venat-Bouvet, L., Ly, K., Szelag, J. C., Martin, J., Labourey, J. L., Genet, D.,
et al. (2003). Thrombotic microangiopathy and digital necrosis: two
unrecognized toxicities of gemcitabine. Anticancer. Drugs 14, 829–832. doi:
10.1097/01.cad.0000098998.92896.01
Vogelzang, N. J., Bosl, G. J., Johnson, K., and Kennedy, B. J. (1981). Raynaud’s
phenomenon: a common toxicity after combination chemotherapy for
testicular cancer. Ann. Intern. Med. 95, 288–292. doi: 10.7326/0003-4819-95-
3-288
von Zastrow, M., and Kobilka, B. K. (1994). Antagonist-dependent and -
independent steps in the mechanism of adrenergic receptor internalization.
J. Biol. Chem. 269, 18448–18452.
White, C. R., Haidekker, M. A., Stevens, H. Y., and Frangos, J. A. (2004).
Extracellular signal-regulated kinase activation and endothelin-1 production
in human endothelial cells exposed to vibration. J. Physiol. 555, 565–572. doi:
10.1113/jphysiol.2003.059899
Wigley, F. M. (2002). Clinical practice. Raynaud’s phenomenon. N. Engl. J. Med.
347, 1001–1008. doi: 10.1056/NEJMcp013013
Wigley, F. M., and Flavahan, N. A. (2016). Raynaud’s phenomenon. N. Engl. J. Med.
375, 556–565. doi: 10.1056/NEJMra1507638
Wigley, F. M., Wise, R. A., Seibold, J. R., McCloskey, D. A., Kujala, G.,
Medsger, T. A., et al. (1994). Intravenous iloprost infusion in patients
with Raynaud phenomenon secondary to systemic sclerosis. A multicenter,
placebo-controlled, double-blind study. Ann. Intern. Med. 120, 199–206. doi:
10.7326/0003-4819-120-3-199402010-00004
William, N. R., and Markowitz, S. B. (2007). Environmental and Occupational
Medicine. Philadelphia: Lippincott Williams & Wilkins.
Wilson, R. H., McCormick, W. E., Tatum, C. F., and Creech, J. L. (1967).
Occupational acroosteolysis. Report of 31 cases. JAMA 201, 577–581. doi:
10.1001/jama.1967.03130080019005
Wise, R. A., Wigley, F. M., White, B., Leatherman, G., Zhong, J., Krasa, H., et al.
(2004). Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor
blocker in recovery from cold-induced vasospasm in scleroderma patients: a
single-center, double-blind, placebo-controlled, randomized crossover study.
Arthritis Rheum. 50, 3994–4001. doi: 10.1002/art.20665
Wood, H. M., and Ernst, M. E. (2006). Renin-angiotensin system mediators
and Raynaud’s phenomenon. Ann. Pharmacother. 40, 1998–2002. doi:
10.1345/aph.1H201
Wu, Y. J., Luo, S. F., Yang, S. H., Chen, J. Y., Yu, K. H., and See, L. C.
(2008). Vascular response of Raynaud’s phenomenon to nifedipine or herbal
medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
Chang Gung Med. J. 31, 492–502.
Yamada, Y., Suzuki, K., Nobata, H., Kawai, H., Wakamatsu, R., Miura, N.,
et al. (2014). Gemcitabine-induced hemolytic uremic syndrome mimicking
scleroderma renal crisis presenting with Raynaud’s phenomenon, positive
antinuclear antibodies and hypertensive emergency. Intern. Med. 53, 445–448.
doi: 10.2169/internalmedicine.53.1160
Zamora, M. R., O’Brien, R. F., Rutherford, R. B., and Weil, J. V. (1990).
Serum endothelin-1 concentrations and cold provocation in primary Raynaud’s
phenomenon. Lancet 336, 1144–1147. doi: 10.1016/0140-6736(90)92766-B
Zhang, X., Hu, Y., Nie, Z., Song, Y., Pan, Y., Liu, Y., et al. (2015). Treatment
of Raynaud’s phenomenon with botulinum toxin type A. Neurol. Sci. 36,
1225–1231. doi: 10.1007/s10072-015-2084-6
Zhao, H., and Lian, Y. (2015). Clinical and image improvement of Raynaud’s
phenomenon after botulinum toxin type A treatment. Australas. J. Dermatol.
56, 202–205. doi: 10.1111/ajd.12326
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Fardoun, Nassif, Issa, Baydoun and Eid. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 13 November 2016 | Volume 7 | Article 438
